News
6d
News-Medical.Net on MSNNew nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapyResearchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to lung adenocarcinoma cells, dramatically suppressing tumor growth in ...
As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances ...
6d
News-Medical.Net on MSNEAGLE model predicts key lung cancer mutations from routine biopsyWith EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.
Researchers find that disrupted circadian rhythms may impair gut regeneration and microbiome balance, heightening colon ...
3d
Vietnam Investment Review on MSNNature Medicine Publishes Innovent’s Promising Phase 1 Gastric Cancer DataIntegrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of ...
The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination ...
During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...
AI model calculates a protein-based stemness index to predict tumor aggressiveness and treatment resistance. Proteomic-based ...
5d
News Medical on MSNAI Tool Gauges Cancer Aggressiveness, Aids New TherapiesAs cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances ...
AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...
Researchers reviewed cases in which patients experienced severe skin toxicities in response to immunotherapy, and sought to identify the distinct natures of these toxicities.
Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results